Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Steve Ubl's departure from PhRMA is a symptom of a larger shift. For a decade, Ubl led the industry's collective lobbying strategy through the pandemic, the Inflation Reduction Act's Medicare drug price negotiations, and the Trump administration's MFN pricing push. PhRMA spent nearly $38 million on lobbying last year, the highest on record. But the administration bypassed PhRMA entirely by negotiating pricing and tariff deals directly with individual company CEOs. Sixteen of the seventeen largest drugmakers signed MFN agreements without PhRMA's involvement. The trade group publicly distanced itself from those deals, but the result was the same: the collective voice was sidelined by bilateral negotiation. Ubl's successor inherits an organization searching for relevance in a policy environment where the White House deals directly with Lilly, Novo, Pfizer, and Merck. Meanwhile, the FDA is making its own moves. Commissioner Makary's FY2027 budget proposes an Expedited IND pathway that could fundamentally change how Phase 1 trials begin, explicitly framing it as a competitive response to China's faster regulatory timelines. 👉 Read Full Analysis

PhRMA's Longest-Serving CEO Is Stepping Down

What Happened: Steve Ubl announced on April 8 that he will step down as president and CEO of PhRMA at the end of 2026 after more than a decade in the role, the longest tenure of any PhRMA CEO in the organization's 68-year history. The board, chaired by Merck CEO Rob Davis, has begun a search for his successor. Ubl will remain until a replacement is appointed.

The Context: Ubl led PhRMA through the COVID-19 pandemic, the passage of the Inflation Reduction Act (which enabled Medicare drug price negotiation over PhRMA's objections), the Trump administration's MFN pricing campaign, and this month's Section 232 tariff announcement. Under his leadership, PhRMA expanded its focus on reining in PBMs, launched campaigns defending the 340B drug discount program, and added major members including Gilead and Genentech. PhRMA spent nearly $38 million on lobbying in 2025, the highest amount on record.

Executive Impact: The timing speaks volumes. Ubl is leaving as PhRMA's institutional model is under pressure from an administration that prefers to negotiate company by company. Sixteen of the seventeen largest pharma companies signed MFN pricing deals directly with the White House. The Section 232 tariff framework rewards individual company cooperation, not collective industry positions. Axios noted that PhRMA lobbyists have expressed frustration at the organization's declining clout. The Washington Post called Ubl "Washington's most powerful drug industry lobbyist." Whoever replaces him will need to rebuild PhRMA's value proposition in an environment where the biggest companies can get better deals by negotiating alone.

FDA Proposes Expedited IND Pathway to Accelerate Phase 1 Trials

What Happened: The FDA released its FY2027 budget request on April 3, totaling $7.2B ($3.3B from congressional appropriations, $3.9B from user fees), a 3.2% increase over FY2026. Within the budget, Commissioner Makary proposed a series of legislative actions, the most significant being a new "Expedited IND" pathway.

The Proposal: The Expedited IND would be an optional, risk-based alternative to the traditional Investigational New Drug process for certain Phase 1 clinical trials. It would allow sponsors to use validated non-animal testing methods (new approach methodologies, or NAMs) to satisfy preclinical requirements, potentially reducing both cost and timeline to first-in-human dosing. The FDA explicitly framed this as a competitive response to China's regulatory framework, which has attracted early-stage drug development activity away from the U.S.

Other Budget Proposals:

Executive Impact: The Expedited IND pathway is the most structurally ambitious FDA reform proposal in years. If implemented, it would disproportionately benefit small biotechs that currently face prohibitive costs in the traditional IND process. Fierce Pharma noted this is Makary laying out "an ambitious legislative wish list" one year into his tenure. The National Law Review called the Paragraph IV head start "a clever, targeted incentive that could meaningfully shift the calculus for companies deciding where to build capacity." Whether Congress acts on any of these proposals, especially with user fee reauthorization negotiations underway, is the open question.

This was the most consequential week in biopharma this year. Here is what happened:

👉 Read Full Analysis

Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here